Imexpharm Corporation (HOSE: IMP)

Imexpharm Income Statement

Financials in millions VND. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	2,161,215	1,994,037	1,643,707	1,266,597	1,369,422	1,402,454
Revenue Growth (YoY)	11.23%	21.31%	29.77%	-7.51%	-2.36%	18.37%
Cost of Revenue	1,192,578	1,010,064	824,152	669,657	750,104	763,396
Gross Profit	968,637	983,973	819,555	596,940	619,318	639,058
Selling, General & Admin	611,936	602,926	523,055	362,868	356,763	436,016
Operating Expenses	611,936	602,926	523,055	362,868	356,763	436,016
Operating Income	356,701	381,047	296,500	234,072	262,555	203,042
Interest Expense	-3,220	-6,036	-3,795	-5,496	-5,408	-3,728
Interest & Investment Income	8,735	19,877	19,853	12,364	7,015	7,015
Currency Exchange Gain (Loss)	2,109	2,613	-2,053	3,436	1,882	2,008
Other Non Operating Income (Expenses)	-17,755	-20,221	-19,448	-9,413	-10,173	-5,811
EBT Excluding Unusual Items	346,570	377,279	291,059	234,963	255,870	202,526
Gain (Loss) on Sale of Investments	1.51	-6.02	345.28	3,896	-429.04	-96.97
Gain (Loss) on Sale of Assets	-3,241	-	-	-	-	-
Pretax Income	343,331	377,273	291,404	238,859	255,441	202,429
Income Tax Expense	70,729	77,717	67,864	49,764	45,744	40,042
Net Income	272,602	299,556	223,540	189,095	209,697	162,387
Preferred Dividends & Other Adjustments	42,974	44,933	39,697	15,582	30,039	19,486
Net Income to Common	229,628	254,623	183,844	173,513	179,658	142,900
Net Income Growth	-7.82%	34.01%	18.22%	-9.82%	29.13%	17.09%
Shares Outstanding (Basic)	154	154	154	154	150	148
Shares Outstanding (Diluted)	154	154	154	154	150	148
Shares Change (YoY)	0.00%	-	-0.00%	2.92%	0.86%	0.01%
EPS (Basic)	1490.99	1653.28	1193.71	1126.63	1200.54	963.11
EPS (Diluted)	1490.89	1653.18	1193.64	1126.63	1200.43	963.11
EPS Growth	-12.62%	38.50%	5.95%	-6.15%	24.64%	17.09%
Free Cash Flow	158,658	-103,064	279,250	182,024	-16,531	-64,535
Free Cash Flow Per Share	1030.18	-669.21	1813.19	1181.89	-110.47	-434.95
Dividend Per Share	454.546	454.546	432.901	649.351	649.351	333.000
Dividend Growth	5.00%	5.00%	-33.33%	0%	95.00%	-50.00%
Gross Margin	44.82%	49.35%	49.86%	47.13%	45.22%	45.57%
Operating Margin	16.50%	19.11%	18.04%	18.48%	19.17%	14.48%
Profit Margin	10.62%	12.77%	11.18%	13.70%	13.12%	10.19%
Free Cash Flow Margin	7.34%	-5.17%	16.99%	14.37%	-1.21%	-4.60%
EBITDA	460,799	463,034	356,886	294,484	315,916	244,251
EBITDA Margin	21.32%	23.22%	21.71%	23.25%	23.07%	17.42%
D&A For EBITDA	104,097	81,987	60,386	60,412	53,361	41,209
EBIT	356,701	381,047	296,500	234,072	262,555	203,042
EBIT Margin	16.50%	19.11%	18.04%	18.48%	19.17%	14.48%
Effective Tax Rate	20.60%	20.60%	23.29%	20.83%	17.91%	19.78%
Revenue as Reported	2,161,215	1,994,037	1,643,707	1,266,597	1,369,422	1,402,454
Advertising Expenses	-	175,099	123,665	110,468	74,360	113,944

Source: S&P Capital IQ. Standard template. Financial Sources.